

I. Requirements for Prior Authorization of Multiple Sclerosis Agents

A. Prescriptions That Require Prior Authorization

Prescriptions for Multiple Sclerosis Agents that meet any of the following conditions must be prior authorized:

1. A non-preferred Multiple Sclerosis Agent. See the Preferred Drug List (PDL) for the list of preferred Multiple Sclerosis Agents at: <https://papdl.com/preferred-drug-list>.
2. A prescription for Ampyra (dalfampridine ER), Aubagio (teriflunomide), Gilenya (fingolimod), Kesimpta (ofatumumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), or Tecfidera (dimethyl fumarate DR).

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Multiple Sclerosis Agent, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. For a natalizumab product, see the Natalizumab policy; **OR**
2. For Zeposia (ozanimod) for the treatment of ulcerative colitis, see the Ulcerative Colitis Agents policy; **OR**
3. Is being treated for a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication; **AND**
4. Is prescribed the Multiple Sclerosis Agent by **one** of the following:
 - a. For Ampyra (dalfampridine ER), a neurologist or physical medicine and rehabilitation (PM&R) specialist
 - b. For all other Multiple Sclerosis Agents, a neurologist;**AND**
5. Does not have a contraindication to the prescribed Multiple Sclerosis Agent; **AND**
6. Is prescribed a dose that is consistent with the FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
7. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
8. For a non-preferred Multiple Sclerosis Agent, **one** of the following:
 - a. Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Multiple Sclerosis Agents approved for the beneficiary's diagnosis
 - b. **One** of the following:
 - i. Has a current prescription (within the past 90 days) for the same non-preferred Multiple Sclerosis Agent (does not apply to non-preferred brands when the

- therapeutically equivalent generic, interchangeable biosimilar, or unbranded biologic is preferred or to non-preferred generics, interchangeable biosimilars, or unbranded biologics when the therapeutically equivalent brand, interchangeable brand, or brand biologic product is preferred)
- ii. For a non-preferred Multiple Sclerosis Agent with a dosing interval exceeding 90 days (e.g., Lemtrada, Mavenclad, Ocrevus), is receiving treatment with the same non-preferred Multiple Sclerosis Agent and will continue therapy at a dosing interval supported by FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature;

AND

9. For Ampyra (dalfampridine ER), has motor dysfunction on a continuous basis that impairs the ability to complete instrumental activities of daily living or activities of daily living; **AND**
10. For Mavenclad (cladribine), has documentation of a recent lymphocyte count within recommended limits according to FDA-approved package labeling before initiating the first treatment course;

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

FOR RENEWALS OF PRIOR AUTHORIZATION FOR MULTIPLE SCLEROSIS AGENTS:
The determination of medical necessity of a request for renewal of a prior authorization for a Multiple Sclerosis Agent that was previously approved will take into account whether the beneficiary:

1. Is prescribed the Multiple Sclerosis Agent by **one** of the following:
 - a. For Ampyra (dalfampridine ER), a neurologist or PM&R specialist
 - b. For all other Multiple Sclerosis Agents, a neurologist;

AND

2. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. Does not have a contraindication to the prescribed Multiple Sclerosis Agent; **AND**
4. **One** of the following:
 - a. For Ampyra (dalfampridine ER), has a documented improvement in motor function
 - b. For all other Multiple Sclerosis Agents, **one** of the following:
 - i. For a Multiple Sclerosis Agent prescribed for a diagnosis of a relapsing form of multiple sclerosis, has documented improvement or stabilization of the multiple sclerosis disease course
 - ii. For a Multiple Sclerosis Agent prescribed for a diagnosis of primary progressive

multiple sclerosis, based on the prescriber's professional judgement, continues to benefit from the prescribed Multiple Sclerosis Agent;

AND

5. For Lemtrada (alemtuzumab), received the previous treatment course at least 12 months prior to the requested treatment course with Lemtrada (alemtuzumab); **AND**
6. For Mavenclad (cladribine), **both** of the following:
 - a. Has documentation of a recent lymphocyte count within recommended limits according to FDA-approved package labeling before initiating the second treatment course
 - b. Has not exceeded the recommended total number of treatment courses according to FDA-approved package labeling;

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Multiple Sclerosis Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. Dose and Duration of Therapy

Requests for prior authorization of Multiple Sclerosis Agents will be approved as follows:

1. For Ampyra (dalfampridine ER) or Aubagio (teriflunomide):
 - a. Initial requests will be approved for up to 3 months.
 - b. Renewal requests will be approved for up to 6 months.
2. For Lemtrada (alemtuzumab):
 - a. Requests for an initial treatment course will be approved for up to 5 days.
 - b. Requests for subsequent treatment courses will be approved for up to 3 days.
3. For Mavenclad (cladribine):
 - a. Requests for prior authorization will be approved for a duration of therapy consistent with FDA-approved package labeling.

MULTIPLE SCLEROSIS AGENTS PRIOR AUTHORIZATION FORM *(form effective 1/8/2024)*

<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:
Name of office contact:			Specialty:
Contact's phone number:			NPI: State license #:
LTC facility contact/phone:			Street address:
Beneficiary name:			City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Dosage form:	Strength:
Directions:	Quantity:	Refills:
Diagnosis <i>(submit documentation)</i> :	Dx code <i>(required)</i> :	Beneficiary's weight:
Is the beneficiary currently being treated with the requested medication?	<input type="checkbox"/> Yes – date of last dose: _____ <i>Submit documentation.</i> <input type="checkbox"/> No	
Is the requested medication being prescribed by or in consultation with a neurologist (or, for Ampyra/dalfampridine, a neurologist or physical medicine and rehabilitation (PM&R) specialist)?	<input type="checkbox"/> Yes <i>Submit documentation of consultation if applicable.</i> <input type="checkbox"/> No	

Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.

INITIAL requests

<input type="checkbox"/> Has a relapsing form of MS <i>(specify)</i> → <input type="checkbox"/> clinically isolated syndrome <input type="checkbox"/> relapsing remitting disease <input type="checkbox"/> active secondary progressive disease <input type="checkbox"/> Has primary progressive MS <input type="checkbox"/> Request is for a NON-PREFERRED Multiple Sclerosis Agent: <input type="checkbox"/> Tried and failed or has a contraindication or an intolerance to the preferred drugs in this class approved for the beneficiary's diagnosis <i>(Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)</i> <input type="checkbox"/> Request is for AMPYRA (dalfampridine): <input type="checkbox"/> Has motor dysfunction on a continuous basis that impairs the ability to complete activities of daily living (ADLs) or instrumental ADLs <input type="checkbox"/> Has results of recent kidney function tests <input type="checkbox"/> Has a history of seizure <input type="checkbox"/> Request is for AUBAGIO (teriflunomide): <input type="checkbox"/> Has results of recent liver function tests <input type="checkbox"/> Request is for GILENYA (fingolimod): <input type="checkbox"/> Has a comorbid heart condition – describe: _____ <input type="checkbox"/> Experienced any of the following in the past 6 months: <input type="checkbox"/> Myocardial infarction <input type="checkbox"/> Transient ischemic attack <input type="checkbox"/> Unstable angina <input type="checkbox"/> Decompensated heart failure requiring hospitalization <input type="checkbox"/> Stroke <input type="checkbox"/> Class III or IV heart failure <input type="checkbox"/> Request is for KESIMPTA (ofatumumab): <input type="checkbox"/> Does not have active hepatitis B virus infection <input type="checkbox"/> Request is for LEMTRADA (alemtuzumab): Dates of previous treatment course(s): _____ <input type="checkbox"/> Request is for MAVENCLAD (cladribine): Dates of previous treatment course(s): _____ <input type="checkbox"/> Has results of a recent lymphocyte count AND: <input type="checkbox"/> Lymphocyte count is within normal limits prior to initiating first treatment course <input type="checkbox"/> Request is for MAYZENT (siponimod): <input type="checkbox"/> Has been tested for CYP2C9 variants to determine CYP2C9 genotype <input type="checkbox"/> Has a comorbid heart condition – describe: _____ <input type="checkbox"/> Experienced any of the following in the past 6 months: <input type="checkbox"/> Myocardial infarction <input type="checkbox"/> Transient ischemic attack <input type="checkbox"/> Unstable angina <input type="checkbox"/> Decompensated heart failure requiring hospitalization <input type="checkbox"/> Stroke <input type="checkbox"/> Class III or IV heart failure

Effective 1/8/2024

☐ **Request is for OCREVUS (ocrelizumab):**

☐ Does not have active hepatitis B virus infection

☐ **Request is for ZEPOSIA (ozanimod):**

☐ Has severe untreated sleep apnea

☐ Will be taking a monoamine oxidase (MAO) inhibitor while taking Zeposia (e.g., selegiline, phenelzine)

☐ Has a comorbid heart condition – describe: _____

☐ Experienced any of the following in the past 6 months:

☐ Myocardial infarction

☐ Unstable angina

☐ Stroke

☐ Transient ischemic attack

☐ Decompensated heart failure requiring hospitalization

☐ Class III or IV heart failure

RENEWAL requests

☐ **For AMPYRA (dalfampridine):**

☐ Experienced an improvement in motor function since starting the requested medication

☐ Has a history of seizure

☐ **For all MS drugs OTHER THAN Ampyra (dalfampridine):**

☐ Has a relapsing form of MS AND:

☐ Experienced improvement or stabilization of the MS disease course since starting the requested medication

☐ Has primary progressive MS AND:

☐ Continues to benefit from the requested medication

☐ **Request is for AUBAGIO (teriflunomide):**

☐ Has results of recent liver function tests

☐ **Request is for GILENYA (fingolimod):**

☐ Has a comorbid heart condition – describe: _____

☐ Experienced any of the following in the past 6 months:

☐ Myocardial infarction

☐ Unstable angina

☐ Stroke

☐ Transient ischemic attack

☐ Decompensated heart failure requiring hospitalization

☐ Class III or IV heart failure

☐ **Request is for KESIMPTA (ofatumumab):**

☐ Does not have active hepatitis B virus infection

☐ **Request is for LEMTRADA (alemtuzumab):** Dates of previous treatment course(s): _____

☐ **Request is for MAVENCLAD (cladribine):** Dates of previous treatment course(s): _____

☐ Has results of a recent lymphocyte count AND:

☐ Lymphocyte count is at least 800 cells/microliter before initiating second treatment course

☐ **Request is for MAYZENT (siponimod):**

☐ Has a comorbid heart condition – describe: _____

☐ Experienced any of the following in the past 6 months:

☐ Myocardial infarction

☐ Unstable angina

☐ Stroke

☐ Transient ischemic attack

☐ Decompensated heart failure requiring hospitalization

☐ Class III or IV heart failure

☐ **Request is for OCREVUS (ocrelizumab):**

☐ Does not have active hepatitis B virus infection

☐ **Request is for ZEPOSIA (ozanimod):**

☐ Has severe untreated sleep apnea

☐ Will be taking a monoamine oxidase (MAO) inhibitor while taking Zeposia (e.g., selegiline, phenelzine)

☐ Has a comorbid heart condition – describe: _____

☐ Experienced any of the following in the past 6 months:

☐ Myocardial infarction

☐ Unstable angina

☐ Stroke

☐ Transient ischemic attack

☐ Decompensated heart failure requiring hospitalization

☐ Class III or IV heart failure

PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION

Prescriber Signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.